Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency
Study Identifier:
LAL-CL08
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Sebelipase Alfa
Date
Jun 2014 - Oct 2018
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - 8 Months
Requirements Information
Sex
Female & Male
Age
N/A - 8 Months
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Sebelipase Alfa
Date
Jun 2014 - Oct 2018
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - 8 Months years
Requirements Information
Protocol Summary
This was an open-label, repeat-dose, study of sebelipase alfa in infants with rapidly progressive lysosomal acid lipase deficiency (LAL-D). Eligible participants received once-weekly infusions of sebelipase alfa for up to 3 years.
Trial Locations
Location
Status
Location
Phoenix, Arizona, United States, 85016
Status
N/A
Location
Kuopio, Finland
Status
N/A
Location
Naples, Italy
Status
N/A
Location
Birmingham, United Kingdom
Status
N/A
Location
Manchester, United Kingdom
Status
N/A